APA (7th ed.) Citation

Clardy, S. M., Uttard, A., Du, B., Catcott, K. C., Lancaster, K. L., Ditty, E., . . . Lowinger, T. B. (2024). Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios. Molecular cancer therapeutics, 23(1), 84-91. https://doi.org/10.1158/1535-7163.MCT-23-0262

Chicago Style (17th ed.) Citation

Clardy, Susan M., et al. "Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles Across a Wide Range of Drug-to-Antibody Ratios." Molecular Cancer Therapeutics 23, no. 1 (2024): 84-91. https://doi.org/10.1158/1535-7163.MCT-23-0262.

MLA (9th ed.) Citation

Clardy, Susan M., et al. "Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles Across a Wide Range of Drug-to-Antibody Ratios." Molecular Cancer Therapeutics, vol. 23, no. 1, 2024, pp. 84-91, https://doi.org/10.1158/1535-7163.MCT-23-0262.